<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656133</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19579</org_study_id>
    <nct_id>NCT03656133</nct_id>
  </id_info>
  <brief_title>Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers</brief_title>
  <official_title>Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy Fractionation for Patients With HPV+ Oropharyngeal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine whether a mathematical model can be used to choose a radiation
      delivery method to improve the rate of a rapid response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators hypothesize that using individual patient proliferation saturation index (PSI)
      to select radiotherapy fractionation (conventional fractionation or hyperfractionation) may
      improve the likelihood of a rapid response (defined as ≥ 32% reduction in volume at 4 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of response at week 4 of treatment</measure>
    <time_frame>At 4 weeks of treatment</time_frame>
    <description>Fractionation of radiation will be individualized based on patient Proliferation Saturation Index (PSI). Objective is to increase the rate of response of ≥ 32% at 4 weeks to 63% of patients, above the expected 49%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete response at 2-3 months</measure>
    <time_frame>2-3 months post treatment</time_frame>
    <description>Rate of complete response by Computed Tomography (CT) at 2 months or Positron Emission Topography (PET)/CT at 3 months following completion of therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Radiotherapy Fractionation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperfractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyperfractionation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy fractionation</intervention_name>
    <description>Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)</description>
    <arm_group_label>Hyperfractionation</arm_group_label>
    <arm_group_label>Standard Fractionation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study

          -  Male or female, aged ≥ 18 years

          -  Pathologically (histologically or cytologically) proven diagnosis of p16+ or HPV+
             squamous cell carcinoma (including the histological variants papillary squamous cell
             carcinoma and basaloid squamous cell carcinoma) of the oropharynx; cytologic diagnosis
             from a cervical lymph node is sufficient in the presence of clinical evidence of a
             primary tumor in the oropharynx. Clinical evidence should be documented, and may
             consist of pathology, palpation, imaging, or endoscopic evaluation, and should be
             sufficient to estimate the size of the primary (for T stage).

          -  American Joint Committee on Cancer (AJCC) 8th edition staging T1-3 N0-1 MO

          -  Patients must have clinically or radiographically evident measurable disease at the
             primary site or at nodal stations.

          -  CT or MRI performed at least 1 week apart. This can consist of diagnostic imaging and
             radiation therapy planning imaging.

          -  No evidence of distant metastases

          -  Eastern Cooperative Oncology Group Performance Status 0 to 3

        Exclusion Criteria:

          -  Age &lt; 18

          -  Positive urine pregnancy test

          -  Evidence of distant metastases

          -  Gross total excision of both primary and nodal disease; this includes tonsillectomy,
             local excision of primary site, and nodal excision that remove all clinically and
             radiographically evident disease

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Patients with a medical condition or social situation that at the discretion of the PI
             would preclude them from completion of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jimmy Caudell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gretchen Macmillan</last_name>
    <phone>813-745-8443</phone>
    <email>gretchen.macmillan@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Macmillan</last_name>
      <phone>813-745-8443</phone>
      <email>gretchen.macmillan@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jimmy Caudell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis B Harrison, MD, FASTRO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andy M Trotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Radiotherapy Fractionation</keyword>
  <keyword>Proliferation Saturation Index</keyword>
  <keyword>Larynx</keyword>
  <keyword>Pharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

